Picture of Perrigo logo

PRGO — Perrigo News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Ireland's Perrigo Q2 profit beats on portfolio streamlining

Ireland's Perrigo Q2 profit beats on portfolio streamlining 


Overview

  • Ireland consumer self-care firm's Q2 revenue slightly beat analyst expectations

  • Adjusted EPS for Q2 beat consensus despite year-over-year decline

  • Company reaffirmed 2026 outlook and completed Dermacosmetics divestiture


Outlook

  • Perrigo reaffirms 2026 adjusted EPS guidance of $2.00 to $2.30 All In, $2.25 to $2.55 Core

  • Company expects 2026 Core organic net sales growth of (3.5)% to +0.5%

  • Perrigo anticipates sequentially stronger second-half 2026 performance driven by cost savings and growth initiatives


Result Drivers

  • CATEGORY SOFTNESS - Co said ongoing softness in consumption and lower retail inventory levels weighed on net sales and margins

  • MARKET SHARE GAINS - Innovation and commercial execution drove market share gains across key categories, per interim CEO Albert Manzone

  • PORTFOLIO STREAMLINING - Completion of Dermacosmetics divestiture contributed to reported EPS and reduced debt


Company press release: ID:nPn9P9mbza


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Slight Beat*

$1.02 bln

$1.01 bln (3 Analysts)

Q2 Adjusted EPS

Beat

$0.50

$0.34 (3 Analysts)

Q2 EPS

$0.63

Q2 Adjusted Gross Margin

35.60%

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Perrigo Company PLC is $15.50, about 43.8% above its August 4 closing price of $10.78

  • The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago


Reuters Recommended Reads

  • Aug 5 - Edgewell Personal Care Q3 sales miss estimates; narrows FY outlook

  • Aug 3 - Clorox Q4 revenue and adjusted EPS beat expectations despite sales drop

  • Aug 3 - Germany's Beiersdorf H1 sales fall, trims FY outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Perrigo

See all news